Source link : https://www.newshealth.biz/health-news/seladelpar-shows-clinically-meaningful-improvements-in-pbc/
MILAN — Seladelpar, an investigational selective peroxisome proliferator-activated receptor delta agonist, achieves both biochemical and clinically meaningful improvements in pruritus and liver injury in patients with primary biliary cholangitis (PBC), both with and without compensated liver cirrhosis, according to two interim analyses of the ASSURE long-term extension study. The first analysis of 337 patients with […]
Author : News Health
Publish date : 2024-06-11 07:23:31
Copyright for syndicated content belongs to the linked Source.